Home / Business and Economy / Ardelyx Eyes $500M Revenue Boost

Ardelyx Eyes $500M Revenue Boost

4 Jun

Summary

Ardelyx anticipates over $500 million in revenue this year.
IBSRELA treatment for IBS-C drives significant revenue outlook.
Company focuses on demand, pipeline, and profitability.

Ardelyx is projecting more than $500 million in top-line revenue for the current year, with its key commercial products, IBSRELA and XPHOZAH, leading the charge. The company's Chief Financial Officer outlined four strategic priorities: boosting IBSRELA demand, maintaining XPHOZAH's growth, progressing its drug pipeline, and ensuring strong financial performance.

IBSRELA, a treatment for irritable bowel syndrome with constipation (IBS-C), is identified as the primary growth driver. Ardelyx research suggests a significant portion of IBS-C patients are not fully satisfied with existing treatments, positioning IBSRELA's unique mechanism of action for success. The company has doubled its IBSRELA sales force and is expanding physician outreach to capture a larger market share.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.